Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol-Myers Squibb Company (BMY) Presents at Citi's 17th Annual BioPharma Conference (Transcript)
12:40pm, Thursday, 08'th Sep 2022
Bristol-Myers Squibb Company (NYSE:BMY ) Citi's 17th Annual BioPharma Conference September 8, 2022 8:50 AM ET Company Participants Adam Lenkowsky - Head of U.S. Commercialization Roland Chen - Head of
Is This Monster Stock On Its Way to Another Multibillion-Dollar Drug?
10:23am, Sunday, 04'th Sep 2022
A promising cancer drug combo from Bristol Myers Squibb is months away from being approved in the European Union to treat patients with a form of skin cancer.
5 Stocks That Michael Burry Just Dumped From His Portfolio
07:30am, Thursday, 01'st Sep 2022
Michael Burry made a name for himself during the Great Recession. His bearish bet against the housing market made the contrarian investor a fortune.
Mario Gabelli's Gabelli Asset Fund 2022 Semiannual Report
06:27pm, Wednesday, 31'st Aug 2022
To Our Shareholders,
Down 6% In A Day, Will Bristol Myers Squibb Stock Rebound?
08:00am, Wednesday, 31'st Aug 2022
Bristol Myers Squibb stock (NYSE: BMY) was down 6% in yesterday's trade, while it's down around 10% in a month.
S&P 500 Stock Market Winners Today
04:30pm, Monday, 29'th Aug 2022
Oil stocks were S&P 500 winners Monday, including Diamondback Energy. Bristol Myers Squibb was among the big losers.
Rethinking rental properties with Landing founder and CEO, Bill Smith
04:22pm, Monday, 29'th Aug 2022
Landing founder and CEO Bill Smith joins 'Closing Bell' to discuss consumer trends towards flexible apartment rentals, the Landing business model and the growing number of flexible housing providers.
Bristol-Myers Squibb stock tumbles after stroke drug trial sees mixed results
03:46pm, Monday, 29'th Aug 2022
Yahoo Finance Live anchors discuss why Bristol-Myers Squibb stock is down today.
Why Bristol Myers Squibb Stock Is Slumping Today
02:25pm, Monday, 29'th Aug 2022
The drugmaker's next-generation blood thinner fails to impress in a mid-stage trial.
Bristol Myers (BMY) Announces Milvexian Phase II Study Results
01:32pm, Monday, 29'th Aug 2022
Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.
Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops
12:24pm, Monday, 29'th Aug 2022
Bristol Myers and Johnson & Johnson's blood thinner fell short of expectations in stroke patients, leading BMY stock to crumble on Monday. The post Bristol Myers Squibb, Bayer Stocks Hit The Deck On B
Bristol-Myers, J&J and Bayer Presenting Key Study Results at Heart Meeting
10:35am, Monday, 29'th Aug 2022
Investors should keep an eye on developments at the European Society of Cardiology meeting, which is underway in Barcelona. News about a new type of heart drug being tested by Bristol-Myers Squibb Co.
Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?
09:47am, Friday, 26'th Aug 2022
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.
Here's Why This Dominant Income Stock Is a Buy
05:30am, Wednesday, 24'th Aug 2022
This company is the undisputed leader in COVID-19 vaccines and treatments.
3 Reasons to Buy This High-Yield Dividend Stock
10:00am, Monday, 22'nd Aug 2022
High-yield stocks tend to outperform during downturns in the broader market.
